Scarica l'app Stockscreener
93.21
16.50%
13.20
Pre-mercato:
93.00
-0.21
-0.23%
Precedente Chiudi:
$80.01
Aprire:
$119.8
Volume 24 ore:
1.12M
Relative Volume:
6.14
Capitalizzazione di mercato:
$725.84M
Reddito:
-
Utile/perdita netta:
$-4.98M
Rapporto P/E:
-70.74
EPS:
-1.3177
Flusso di cassa netto:
$-3.85M
1 W Prestazione:
+22.89%
1M Prestazione:
+15.79%
6M Prestazione:
+228.55%
1 anno Prestazione:
+125.09%
Intervallo 1D:
$89.29
$123.75
Intervallo di 1 settimana:
$72.03
$123.75
Portata 52W:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Nome
Bright Minds Biosciences Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta DRUG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
93.21 | 623.05M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | BTIG Research | Buy |
| 2025-05-13 | Iniziato | TD Cowen | Buy |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-01-23 | Iniziato | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
Will Bright Minds Biosciences Inc. stock deliver shareholder value - Улправда
Bright Minds Biosciences: Analyzing the Surge - StocksToTrade
Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders - TipRanks
Bright Minds Seizure Treatment Trial Wraps Up - timothysykes.com
Bright Minds Biosciences launches $100 million public offering - MSN
Bright Minds Biosciences launches $100 million public offering By Investing.com - Investing.com India
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering - marketscreener.com
Biotech’s $100M cash plan to fund new seizure and rare disease trials - Stock Titan
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Analyzing Bright Minds Biosciences’ Recent Stock Surges - timothysykes.com
Market movers: Bright Mind Biosciences, Sandisk, Under Armour… - Proactive Investors
Bright Minds Stock Surges 22% After Positive Phase 2 Topline Results - Nasdaq
Bright Minds Biosciences (NASDAQ:DRUG) Price Target Raised to $147.00 - MarketBeat
New epilepsy medication from Bright Minds reduces seizures, boosting stock price on Tuesday - Bitget
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Benzinga
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 12-Month HighWhat's Next? - MarketBeat
Bright Mind Biosciences shares surge on positive epilepsy drug trial results - Proactive financial news
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why did DRUG stock rocket 51% today? - MSN
Market movers: Bright Mind Biosciences, Sandisk, Under Armour, OPT… - Proactive financial news
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Australia
Bright Minds reports positive Phase 2 results for epilepsy drug - Investing.com
Bright Minds posts mid-stage trial win for lead drug (DRUG) - Seeking Alpha
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) - The Manila Times
Bright Minds Biosciences stock climbs after positive Phase 2 trial results - Investing.com Canada
DRUG: BMB-101 achieved robust seizure reduction and improved REM sleep in drug-resistant epilepsy - TradingView — Track All Markets
Bright Minds Biosciences Announces Positive Topline Results - GlobeNewswire
Experimental drug sharply cuts hard-to-treat seizures, boosts REM - Stock Titan
(DRUG) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Bright Minds To Unveil Topline Results For BMB-101 Phase 2 Trial In Absence Seizures And DEE - Nasdaq
Bright Minds Biosciences Stock Pre-Market (+10%) : BMB-101 Phase 2 Topline Data Release - Trefis
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Bright Minds Biosciences Sets January 6 Webcast for BMB-101 Phase 2 Topline Results in Drug-Resistant Absence Seizures - TipRanks
Bright Minds to announce topline results for BMB-101 phase 2 trial on Jan 6 - marketscreener.com
Bright Minds to report Phase 2 epilepsy drug trial results Tuesday - Investing.com Australia
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - The Manila Times
Bright Minds to report Phase 2 epilepsy drug trial results Tuesday By Investing.com - Investing.com South Africa
New trial results in drug-resistant seizures to be revealed Tuesday - Stock Titan
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 5.7%Time to Sell? - MarketBeat
Bright Minds Biosciences’ (DRUG) Buy Rating Reaffirmed at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
HC Wainwright Has Negative Outlook for DRUG Q1 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% HigherHere's Why - MarketBeat
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target By Investing.com - Investing.com South Africa
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen - MarketBeat
Bright Minds Biosciences (DRUG) Expected to Announce Quarterly Earnings on Monday - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Large Volume Increase – Time to Buy? - Defense World
Bright Minds Biosciences Inc Azioni (DRUG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):